Patents by Inventor Kevin McDonnell

Kevin McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11261214
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: March 1, 2022
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
  • Patent number: 11215257
    Abstract: A shock absorbing system for impact energy dissipation employs removable unitary cells of compressible members in communication with a reservoir and containing a first working fluid. Resilient structural members may be placed intermediate the compressible members to deform responsive to compression to provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state.
    Type: Grant
    Filed: December 16, 2018
    Date of Patent: January 4, 2022
    Inventor: Kevin McDonnell
  • Publication number: 20210299210
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Application
    Filed: April 2, 2019
    Publication date: September 30, 2021
    Inventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya
  • Publication number: 20210147484
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 20, 2021
    Inventors: Paul BESWICK, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20210101937
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Gemma MUDD, Punit Upadhyaya, Kevin McDonnell
  • Publication number: 20210069287
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Application
    Filed: July 29, 2020
    Publication date: March 11, 2021
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 10919937
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 16, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 10875894
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 29, 2020
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya
  • Publication number: 20200291096
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 14, 2018
    Publication date: September 17, 2020
    Inventors: Nicholas Keen, Kevin McDonnell, Peter U. Park
  • Publication number: 20200283482
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 14, 2018
    Publication date: September 10, 2020
    Inventors: Nicholas Keen, Kevin McDonnell, Peter U. Park, Gemma Elizabeth Mudd, Gabriela Ivanova-Berndt
  • Publication number: 20200255477
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: August 3, 2018
    Publication date: August 13, 2020
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
  • Publication number: 20200131228
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 30, 2020
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20200130743
    Abstract: A trailer assembly with improved lateral support structure and steering system control of the axial wheels on a front elongated trailer and a rear elongated trailer to remain in a collinear following configuration to carry elongated loads extending over the extended lengths of the combination of the front elongated trailer and the rear elongated trailer and allow ready turning control.
    Type: Application
    Filed: December 27, 2019
    Publication date: April 30, 2020
    Applicant: SLINGSHOT HAULAGE PTY LTD
    Inventors: Leigh Dehne, Kevin McDonnell
  • Publication number: 20200116225
    Abstract: A shock absorbing system for force attenuation, impact modification or reduction, employs an envelope having a chamber containing a first working fluid, the envelope deformable in response to the impulse to attenuate impact force. A plurality of resilient supplemental absorber elements dispersed within the chamber. The plurality of resilient supplemental absorber elements are deformable in response to the force to assist in attenuating impact force and provide additional resilient restoring force to return the envelope to a pre-impact shape. In alternative implementations, a unitary cell for energy dissipation employs an envelope having a chamber containing a first working fluid and an inner element contained within the chamber and having an inner chamber containing a second working fluid.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Inventors: Kevin McDonnell, Alexandra McDonnell
  • Patent number: 10588935
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 17, 2020
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
  • Publication number: 20200030232
    Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 30, 2020
    Applicant: TGX SOFT CHEW, LLC
    Inventors: Kevin McDonnell, Joanna ROSSI, Scott ECCLES, Gueorgui PUCHKAROV
  • Publication number: 20200023034
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Application
    Filed: March 6, 2019
    Publication date: January 23, 2020
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin Mcdonnell, Rosa Maria Silva Garcia Grenha
  • Publication number: 20190307836
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Application
    Filed: April 2, 2019
    Publication date: October 10, 2019
    Inventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya
  • Publication number: 20190263866
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 29, 2019
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Elizabeth Mudd, Peter U. Park, Punit Upadhyaya
  • Publication number: 20190154101
    Abstract: A shock absorbing system for impact energy dissipation employs removable unitary cells of compressible members in communication with a reservoir and containing a first working fluid. Resilient structural members may be placed intermediate the compressible members to deform responsive to compression to provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state.
    Type: Application
    Filed: December 16, 2018
    Publication date: May 23, 2019
    Inventor: Kevin McDonnell